Dr. Elizabeth Gillies is well-versed in using CRISPR/Cas9 genome-editing technology for creating advanced cell-based models. Watch the presentation to learn how this cutting edge technology was used to enhance virus production in ATCC cell lines
Most viral vaccines are manufactured in large-scale tissue culture systems using historical cell lines that are approved for vaccine manufacturing.
- ATCC used CRISPR/Cas9 gene-editing techniques to increase the viral production efficiency of some of these historical cell lines.
- These enhanced virus-producing cell lines have the potential to significantly reduce the costs associated with generating viral vaccines and high-titer viral stocks.